Join us this Thursday, 2/27, for an exciting look at the next generation of blood-based predictive biomarkers for therapy selection.

Your partner for clinical glycoproteomics

At InterVenn, we're harnessing the power of the glycoproteome to deliver powerful new tools for precision medicine.

Our unique liquid biopsy platform is driving new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring

Discover GlycoVision

Precise Glycoprotein Quantification

Our powerful platform comprehensively analyzes glycoproteins by identifying and characterizing their structures, precisely mapping glycosylation sites, and determining specific glycan motifs.

For the first time, we can accurately quantify intact glycopeptides, providing crucial insights into precision medicine events, biological roles, and functions.

Learn About Glycoproteomics

Who We Are

We're a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics.

Clinical Evidence

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Journal of Hematology & Oncology | March 22, 2024

Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling

Gastroenterology | September 25, 2023

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Frontier in Immunology | June 13, 2023

Get in touch